VR Logo

Eledon Pharmaceuticals Inc. (ELDN) download report


Healthcare | Biotechnology & Pharma Research

Eledon Pharmaceuticals Inc. (ELDN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.

IPO Date: 17-Sep-2014

CEO & Non Independent Director: Dr. David-Alexandre C. Gros M.D., Ph.D.

Pres, Chief Scientific Officer & Non Independent Director: Dr. Steven N. Perrin Ph.D.

Listing: NASDAQ: ELDN

Country: United States

Headquarters: Irvine, CA

Website: https://eledon.com

Key Facts

Market cap: $35.91 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-35.87 Mln

Cash: $76.68 Mln

Total Debt: $0.68 Mln

Insider's Holding: 9.78%

Liquidity: Low

52 Week range: $2.26 - 8.49

Shares outstanding: 13,756,800

10 Years Aggregate:

  • CFO: $-208.50 Mln
  • EBITDA: $-220.80 Mln
  • Net Profit: $-224.75 Mln

Stock Performance

Time Period Eledon Pharmaceuticals (ELDN) S&P BSE Sensex S&P Small-Cap 600
YTD-39.00-9.49-17.79
1 month-15.67-2.87-2.72
3 months-29.02-8.59-12.17
1 Year-65.690.81-15.82
3 Years-47.7910.397.14
5 Years-52.2211.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Eledon Pharmaceuticals (ELDN) S&P Small-Cap 600 S&P BSE Sensex
2021-71.3625.2721.99
202047.519.5715.75
2019-63.7520.8614.38
2018-60.39-9.705.87
2017-53.8711.7327.91
2016-88.7924.741.95
2015-40.84-3.36-5.03